
    
      INTERVENTION It will be a randomized controlled trial which will be done on COVID-19 patients
      proven by PCR fulfilling the criteria (asymptomatic/mild to moderate severity). They will be
      divided into two groups after randomization. Group A will be administered Ivermectin single
      dose of 12grams along with Chloroquine as per existing hospital guidelines and group B will
      be given Chloroquine alone. Dose of Ivermectin to be repeated at 1 week if PCR stays
      negative. PCR will be done on alternate days (48, 96 and 144hours) and the duration at which
      the PCR becomes negative will be compared. Dose of drug subject to change in accordance with
      patient response or possible side effect.

      ELIGIBILITY CRITERIA INCLUSION CRITERIA

      In order to be eligible to participate in this study, an individual must meet all of the
      following criteria:

      Provision of signed and dated informed consent form Stated willingness to comply with all
      study procedures and availability for the duration of the study Male or female, aged 15 to 65
      years In good general health with no or mild symptoms of Corona virus disease PCR positive
      for SARS-Cov-2. Ability to take oral medication and be willing to adhere to the drug intake
      regimen EXCLUSION CRITERIA

      An individual who meets any of the following criteria will be excluded from participation in
      this study:

      Severe symptoms likely attributed to Cytokine Release Storm. Malignant diseases, diabetes
      mellitus, chronic kidney disease and cirrhosis liver with CPT class B or C.
    
  